- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03455335
Autologous Stem Cells for the Treatment of No Option Critical Limb Ischemia
A Phase 1b, Open Label, Uncontrolled, Non-randomized Dose-escalation Study to Examine the Safety of Intramuscular Autologous Transplantation of Escalating Doses of Mesenchymal Stem Cells to Patients With no Option Critical Limb Ischemia.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a phase 1b, open label, uncontrolled, non-randomized dose-escalation study to examine the safety of intramuscular autologous transplantation of escalating doses of mesenchymal stem cells to patients with no option critical limb ischemia.
Trial Aims and Objectives: To examine the safety of intramuscular transplantation of escalating doses of autologous bone marrow derived mesenchymal stem cells to patients with no option critical limb ischemia.
Patient Population: Patients with critical limb ischemia who are not candidates for revascularization.
Trial Setting:HRB Clinical Research Facility Galway and Galway University Hospitals.
Trial Intervention:Intramuscular delivery of autologous bone marrow-derived mesenchymal stem cells to patients with no option critical limb ischemia.
Study Design: Open label, uncontrolled, non-randomized, dose escalation study. Sample Size: 9 Method of Participant Assignment:Sequential administration of 3 escalating doses of autologous bone marrow-derived mesenchymal stem cells.
Examination Points: Day 0, 7, 30, 90, 180, 365 and 730 Primary Outcome: Serious adverse events that are attributable to intervention. Secondary Outcomes :Amputation free survival, median time to amputation, TcPo2, ABI, pain scale, ulcer healing, quality of life assessments, collateral vessel formation detected by MRI at 12 months.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Galway
-
Galway City, Galway, Irland
- Galway University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Each patient must meet all of the following inclusion criteria to be enrolled into the study
- Men and women between the ages of 18 and 85
- Voluntary written informed consent, given before performance of any study-related procedure not part of standard medical care, and with the understanding that consent may be withdrawn at any time without prejudice to future medical care
- Presented with CLI with rest pain or ulceration with no option for revascularization agreed by an expert panel including an interventional radiologist and vascular surgeon; CLI defined as persistent ischemic rest pain for greater than or equal to 2 weeks and/or ulceration or gangrene of the toe or foot
- Estimated life expectancy > 6 months as deemed by patient's clinician and/or investigator
- Suitable candidate for a bone marrow aspiration, deemed by Consultant Haematologist
- Chronic critical limb ischaemia with rest pain (Rutherford Class 4) or mild-to-moderate tissue loss (Rutherford Class 5) who are not candidates for revascularisation
- Medically fit to undergo bone marrow harvest and stem cell intramuscular injection
- One of the following haemodynamic parameters: ankle systolic pressure < 70 mmHg or ABI <0.9 TBI <0 .6 TcPO2 <60mmHg on room air
Exclusion Criteria:
Patients meeting any of the following exclusion criteria are not to be enrolled in the study:
- Has received prior therapy with MSCs
- Has had previous amputation of the talus or above
- Has failed revascularization within 2 weeks before entry to the study
- Known Aortoiliac disease with > 50% stenosis
- Contraindication to intramuscular procedure, including active infection in the affected limb, or wet gangrene or exposed bone or tendon in lower limb with CLI, or in the opinion of the attending clinician, is unsuitable for intramuscular procedure
- Severe co-morbidity limiting 6 month survival of patients
- Abnormal liver function as defined by AST and ALT > 2.5 fold the ULN and total bilirubin > 1.5 ULN
- Significant cognitive impairment (Mini Mental Status Examination <22)
- Presence of proliferative retinopathy (in participants with diabetes mellitus only)
- Presence of poorly controlled diabetes mellitus with HbAIc > 10% within previous 3 months
- HIV or HBsAg positive
- Presence of acute coronary syndrome
- Patient has known active malignancy
- Pregnancy
- Likely inability to comply with the protocol or cooperate fully with the investigator and site personnel
- Patient taking other investigational drugs at the time of enrolment or within 28 days of enrolment
- Rutherford class 6 CLI
- Significant bone marrow dysfunction, based on assessment by Haematologist or an established diagnosis of myelodysplasia, or myeloproliferative disorder etc.
- Bleeding diathesis, coagulopathy, thrombocytopenia etc.
- Patients in whom delay incurred by attempts at limb salvage using MSCs will adversely affect prognosis in the opinion of the responsible attending clinician
Patients with known allergy to foetal bovine serum or trypsin
-
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: low dose cohort
20 million hMSCs .
|
Andre navne:
|
Eksperimentel: mid dose cohort
40 million hMSCs
|
Andre navne:
|
Eksperimentel: high dose cohort
80 million hMSCs .
|
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
The number of Serious Adverse Events that are attributable to the treatment
Tidsramme: 12 months
|
The number of Serious Adverse Events that are attributable to the MScs
|
12 months
|
The severity of Serious Adverse Events that are attributable to the treatment
Tidsramme: 12 months
|
The number of Serious Adverse Events that are attributable to the MScs
|
12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Amputation free survival
Tidsramme: 12 months
|
Efficacy measured by the presence or absence of the target limb
|
12 months
|
median time to amputation,
Tidsramme: 12 months
|
Efficacy measured by the duration from time of cell administration to time of amputation if applicable.
|
12 months
|
Change in Transcutaneous Pressure of Oxygen TcPO2
Tidsramme: 12 months
|
Efficacy will be determined by improvement from baseline in mmHg
|
12 months
|
Change in Ankle Brachial Index
Tidsramme: 12 months
|
"Ankle Brachial Index: An indicator of peripheral perfusion measured by dividing Ankle Pressure (mmHg) by brachial pressure (mmHg) (normal ABI is 1.0 ).
Efficacy outcome will be measured by improvement from baseline .
The higher the ABI, the better the outcome."
|
12 months
|
Collateral vessel formation
Tidsramme: 12 months
|
Efficacy will be determined the presence of collateral vessel formation as detected by MRI
|
12 months
|
Change in Ischemic rest pain
Tidsramme: 12 months.
|
Efficacy will be determined by decrease in score from baseline as measured by verbal analogue scale (0 = no pain, 10 = worst pain in life)
|
12 months.
|
Change in Ulcer size
Tidsramme: 12 months.
|
Efficacy will be determined by decrease in the surface area from baseline as measured by ImageJ software and or complete healing of the ulcer
|
12 months.
|
Change in Quality of Life
Tidsramme: 12 months.
|
Efficacy will be measured using the EQ 5D Quality of Life assessment tool
|
12 months.
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Timothy O Brien, PhD, NUIG
Publikationer og nyttige links
Generelle publikationer
- Mohamed SA, Howard L, McInerney V, Hayat A, Krawczyk J, Naughton S, Finnerty A, Holohan M, Duffy A, Moloney T, Kavanagh E, Burke P, Liew A, Tubassam M, Walsh SR, O'Brien T. Autologous bone marrow mesenchymal stromal cell therapy for "no-option" critical limb ischemia is limited by karyotype abnormalities. Cytotherapy. 2020 Jun;22(6):313-321. doi: 10.1016/j.jcyt.2020.02.007. Epub 2020 Apr 6.
- EU Clinical Trials Register Clinical trial results 2013-003447-37 version 1 EU-CTR publication date: of 21 01 January 2021
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2013-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kritisk lemmeriskæmi
-
Unity Health TorontoUkendtUddannelse, Medicin | Critical Care UltralydCanada
-
Unity Health TorontoAfsluttet
-
Nanjing PLA General HospitalAfsluttetCritical Care Patient; Nedre fordøjelseskanal lidelse; | Colon læsioner;
-
Heidelberg UniversityUkendtSedation af cerebrovaskulært ventilerede Critical Care-patienterTyskland
-
Cooperative International Neuromuscular Research...Carolinas Medical Center lead study siteAfsluttetBeckers muskeldystrofi | Limb-Girdle Muskeldystrofi, Type 2A (Calpain-3-mangel) | Limb-Girdle Muskeldystrofi, Type 2B (Miyoshi Myopati, Dysferlin-mangel) | Limb-Girdle Muskeldystrofi, Type 2I (FKRP-mangel)Forenede Stater
-
Linda Pax LowesRekrutteringLimb-Girdle Muskeldystrofi Type 2A | Limb-Girdle Muskeldystrofi, Type 2EForenede Stater
-
ML Bio Solutions, Inc.RekrutteringLimb-Girdle Muskeldystrofi Type 2I (LGMD2I)Forenede Stater, Holland, Det Forenede Kongerige, Danmark, Australien, Italien, Norge
-
National Taiwan University Clinical Trial CenterRekrutteringKardiologi, Critical Care Medicine, Emergency Medical ServiceTaiwan
-
University Hospital of North NorwayUniversity of Tromso; Norwegian Muscle Disease Association (FFM); Norwegian... og andre samarbejdspartnereAktiv, ikke rekrutterendeMuskeldystrofier | Lembælte muskeldystrofi | Lembælte muskeldystrofi, type 2I | Limb urdle muskeldystrofi R9 FKRP-relateretNorge
-
Emory UniversityBoston Scientific CorporationAfsluttet
Kliniske forsøg med 20 million hMSCs
-
Mathematica Policy Research, Inc.RAND; Centers for Medicare and Medicaid ServicesUkendtHjerte-kar-sygdomme
-
BLIS Technologies LimitedIkke rekrutterer endnu
-
BayerAfsluttet
-
Million Marker Wellness, Inc.AfsluttetMiljøeksponering | Undersøgelse | Sundhedskompetence | Hormonforstyrrende kemikalier | Phthalat eksponering | Bisphenol AForenede Stater
-
NYU Langone HealthAgency for Healthcare Research and Quality (AHRQ)AfsluttetKardiovaskulær sygdom | Højt blodtrykForenede Stater
-
RIVAGESIkke rekrutterer endnuKronisk sygdom | Overholdelse af medicin | Polypatologi | Ældre Person | Digital applikation
-
Region Örebro CountyIkke rekrutterer endnuMekanisk ventilation | Atelektase | Distribution af ventilation
-
Aspire Health ScienceUkendtCOVID-19 lungebetændelse
-
Assistance Publique - Hôpitaux de ParisAfsluttetHypoxi | Infertilitet | Embryo kultur